FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order

WHY IT MATTERS

Patients with treatment-resistant mental illness conditions may gain faster access to new therapies through streamlined FDA review processes and accelerated approval pathways.

President Trump signed an executive order on April 18 directing the federal government to speed up access to treatments for serious mental illness, including conditions that are hard to treat. This means the FDA and other health agencies will work faster to get new mental health treatments to patients who need them.

On April 18, President Trump issued an Executive Order directing the U.S. Department of Health and Human Services (HHS) to accelerate access to treatments for patients with serious mental illness, including devastating, complex, and treatment-resistant conditions.